Market Overview

UPDATE: Piper Jaffray Raises PT on LHC Group on Q4 Earnings, FY13 EPS Guidance

Related LHCG
Markets Edge Lower; Zumiez Issues Weak Outlook
Top 4 Stocks In The Home Health Care Industry With The Highest ROE

In a report published Monday, Piper Jaffray reiterated its Overweight rating on LHC Group (NASDAQ: LHCG), and slightly raised its price target from $21.00 to $22.00.

Piper Jaffray noted, “Organic admissions growth of 5.6% was solid and the company continues to receive an increasing amount of inbound calls about hospital partnership opportunities. Although the recently completely Addus Home Health acquisition is expected to be neutral to FY13 earnings, we believe Addus could approach corporate margins in 2014 and accretion could be in the neighborhood of $0.20-$0.25 assuming 100 bps of overall G&A leverage.”

LHC Group closed on Friday at $20.35.

Latest Ratings for LHCG

DateFirmActionFromTo
Aug 2014Credit SuisseMaintainsUnderperform
Aug 2014OppenheimerMaintainsOutperform
Mar 2014RBC CapitalUpgradesUnderperformSector Perform

View More Analyst Ratings for LHCG
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Analyst Ratings

 

Related Articles (LHCG)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters